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INTRODUCTION
During developmental angiogenesis, arteries, veins and lymphatics
arise from pre-existing vessels by carefully regulated processes of
sprouting, migration, proliferation and patterning of endothelial
cells, collectively termed haemangiogenesis (for arteries and veins)
or lymphangiogenesis (for lymphatic vessels). In the zebrafish
embryonic trunk, developmental angiogenesis takes place in two
distinct stages: primary sprouts form from the dorsal aorta to give
rise to intersegmental vessels from ~22 hours post-fertilisation (hpf),
and then secondary sprouts form from the posterior cardinal vein
(PCV) to give rise to intersegmental veins and lymphatic vascular
precursors from ~32 hpf (Isogai et al., 2003; Yaniv et al., 2006).
Although primary sprouts will contribute to both functional arteries
and veins after the later remodelling of the trunk vasculature (Isogai
et al., 2003), primary sprouting is considered an arterial angiogenic
process as sprouts derive exclusively from the dorsal aorta and
express arterial markers (Siekman and Lawson, 2007), whereas
secondary sprouting from the PCV is a venous angiogenic process.
These processes are regulated by vascular endothelial growth factors
and their receptors. The primary sprouting of intersegmental arteries
(ISAs) is dependent on Vegfa, Kdr and Kdr-l (Bahary et al., 2007;
Bussmann et al., 2008; Covassin et al., 2009; Covassin et al., 2006;
Habeck et al., 2002) and the growth of ISAs has been reported to
stall transiently upon morpholino (MO) knockdown of Flt4 or Vegfc
(Covassin et al., 2006). flt4 and vegfc are essential for
lymphangiogenesis in the zebrafish trunk (Kuchler et al., 2006;
Yaniv et al., 2006) and vegfc is required at the level of venous
angiogenic sprouting (Hogan et al., 2009).
Mouse mutants or transgenic mice deficient for the ligand Vegfc,
or for signalling by its receptor Flt4, lack lymphatic vessels and
consequently display lymphedema (Karkkainen et al., 2004; Makinen
et al., 2001; Veikkola et al., 2001). Vegfc-deficient mice lack
lymphatic vessels owing to a block in lymphangiogenesis that occurs
at the level of budding of lymphangioblasts from venous endothelium,
the earliest event in lymphatic vascular differentiation (Karkkainen et
al., 2004). Consistent with the established functions of these factors
during development, Vegfc and Flt4 drive tumour lymphangiogenesis
(Karpanen et al., 2001), their antagonists inhibit tumour metastasis
(He et al., 2002) and FLT4 mutations lead to primary (inherited)
lymphedema in humans (Karkkainen et al., 2000).
A recent study has demonstrated a role for Flt4 in
haemangiogenesis (Tammela et al., 2008). The inhibition of Flt4
reduced angiogenic sprouting of blood vessels during retinal or
tumour-associated angiogenesis (Tammela et al., 2008). Consistent
with this role, Flt4 is expressed in intersegmental vessels in the trunk
of the developing mouse embryo and in the vasculature of the retina
during angiogenesis, with enhanced expression in sprouting tip cells
(Tammela et al., 2008). Notch signalling generally acts to robustly
repress the angiogenic potential of endothelial cells during
development and disease (Hellstrom et al., 2007; Noguera-Troise et
al., 2006; Siekmann and Lawson, 2007; Suchting et al., 2007).
Consistent with this model, Dll4 inhibition leads to dramatically
increased angiogenesis that produces morphologically abnormal and
non-functional blood vessels (Leslie et al., 2007; Noguera-Troise et
al., 2006; Siekmann and Lawson, 2007). During retinal
angiogenesis, Dll4-induced signalling suppresses Flt4 expression in
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endothelial tip cells, but when Dll4 or Notch signalling is inhibited,
upregulated Flt4 activity drives ectopic sprouting and increased
angiogenesis (Tammela et al., 2008).
During arterial angiogenesis in zebrafish, increased vessel
sprouting induced by the loss of the Notch target transcription factor
Rbpsuh (Rbpja – Zebrafish Information Network) can be
suppressed, at least in part, by the depletion of Flt4 using MOs,
indicating that there is likely to be a conserved relationship between
Notch signalling and Flt4 function in zebrafish arteries (Siekmann
and Lawson, 2007). During both arterial and venous angiogenesis,
there is a constant source of vegfc in the zebrafish trunk, expressed
first in the hypochord and then in the dorsal aorta (Covassin et al.,
2006). Zebrafish flt4 expression is found at high levels in venous
endothelial cells during both arterial and venous angiogenesis, but
has also recently been identified in arterial cells (Covassin et al.,
2009; Siekmann and Lawson, 2007). The presence of a constant
source of ligand in the developing embryo, as well as receptor
expression in sprouting endothelial cells during both arterial and
venous angiogenesis, raises the question of how developing arteries
and veins are programmed to differentially respond to Vegfc/Flt4
signalling and what role Notch signalling might play.
Here, we report the identification of a Flt4 signalling-deficient
zebrafish mutant and investigate the relationship between Dll4
function in arteries and Vegfc/Flt4 signalling in the developing
vasculature. As with vegfc, flt4 is required for all venous-derived
angiogenesis in the zebrafish trunk, both in lymphangiogenesis and
for the formation of intersegmental venous sprouts. Surprisingly,
arterial angiogenesis is normal in zebrafish flt4 signalling-deficient
mutants, and we show that dll4 suppresses Vegfc/Flt4 signalling in
zebrafish arteries in order to allow for normal ISA development.
Analysis of the expression of vegfc and flt4 in dll4-deficient arteries
indicates that this suppression is not due to any observable changes
in ligand or receptor transcription. We propose that this role of dll4
contributes to the differential response of arteries and veins to a
constant source of Vegfc in the trunk of the embryo during
developmental angiogenesis.
MATERIALS AND METHODS
Zebrafish
All zebrafish strains were maintained in the Hubrecht Institute under
standard husbandry conditions. Animal experiments were performed in
accordance with the rules of the Animal Experimentation Committee of the
Royal Netherlands Academy of Arts and Sciences (DEC). The published
transgenic lines used were TG(fli1a:gfp)y1 (Lawson and Weinstein, 2002),
TG(flt1:YFP)hu4624 (Hogan et al., 2009) and TG(kdr-l:Cherry)s916 (Hogan et
al., 2009). Embryos genotyped in Fig. 4 were of the TG(fli1a:gfp)y1 strain.
ENU mutagenesis was performed as previously described (Wienholds et
al., 2002). The F1 progeny of mutagenised males were crossed to the
TG(fli1a:gfp) strain to produce transgenic F2 families. Subsequent in-
crossing of F2 progeny generated F3 embryos that were screened for the
presence or absence of the thoracic duct.
Positional cloning of expando
The flt4hu4602 mutation was mapped using standard meiotic mapping with
simple sequence length polymorphisms (SSLPs). The primers used for
SSLP markers depicted in Fig. 2 were: z43267, 5-CAAAGGGTGC -
AAAGTGCATT-3 and 5-AGCAAAAGTGCTGGTGATCA-3; z26376,
5-CCTGCTAACCTGCGTTCTTC-3 and 5-CGTTAGCATATGCGCA -
CTCT-3; z11725, 5-GCTTCCAGAAGTGGAGCAAC-3 and 5-TGA -
TTTTGATTGGGGACCAT-3. Subsequent genotyping and SNP analyses
were performed by sequencing using the primer pair 5-AGCTCTTG -
ATTTGGCTTTAG-3 and 5-GGAAAGTATCCTTGCTCTGC-3. Bioin-
formatic construction of the genomic region was performed using the
Ensembl database (http://www.ensembl.org), release 44, April 2007.
FLT4 kinase assay
Full-length human wild-type FLT4 and I1034S mutant FLT4 constructs were
cloned into the pMXs vector (a generous gift from Dr Toshio Kitamura,
University of Tokyo, Japan) and transfected into HEK 293T cells (American
Type Culture Collection) grown in DMEM supplemented with 10% foetal
bovine serum (FBS) (PromoCell), glutamine and antibiotics. For
immunoprecipitation and immunoblotting analysis, confluent plates of the
cells were serum-starved for 2 hours, stimulated with VEGF-C (100 ng/ml)
and lysed in lysis buffer (50 mM HEPES pH 7.5, 1% Triton X-100, 5%
glycerol, 1 mM EGTA, 150 mM NaCl, 1.5 mM MgCl2, 100 mM NaF, 1 mM
each Na3VO4, PMSF, aprotinin and leupeptin) (Saharinen et al., 1997).
Equal amounts of protein in the lysates were used for immunoprecipitation
using mouse monoclonal anti-human FLT4 antibodies (9D9) (Petrova et al.,
2008). The immunocomplexes were captured using protein-G sepharose
(GE Healthcare Bio-Sciences, Uppsala, Sweden), separated by 7.5% SDS-
PAGE, transferred to a nitrocellulose membrane and detected using
monoclonal mouse anti-phosphotyrosine (4G10; Upstate Biotechnology,
Lake Placid, NY, USA) or rabbit anti-human FLT4 antibodies, biotinylated
secondary antibodies (Dako Denmark, Glostrup, Denmark) and streptavidin-
biotinylated horseradish peroxidase complex (GE Healthcare, Little
Chalfont, UK), followed by enhanced chemiluminescence detection with
the SuperSignal West Femto Maximum Sensitivity Substrate (Pierce,
Rockford, IL, USA). For re-probing, the membranes were stripped for 15
minutes at room temperature using Re-Blot Plus Strong Solution
(Chemicon).
mRNA and morpholino (MO) injections
MOs targeting the vegfc and flt4 start codons were: flt4 ATG MO, 5-
CTCTTCATTTCCAGGTTTCAAGTCC-3 (Open Biosystems) and vegfc
ATG MO, 5-GAAAATCCAAATAAGTGCATTTTAG-3 (Genetools);
both were injected at 5 ng/embryo. The dll4 MO targeted the exon 4/intron
4 splice-donor site (5-TGATCTCTGATTGCTTACGTTCTTC-3) and was
injected at 3 ng or 6 ng/embryo as indicated.
The sFLT4, vegfc and vegfd cDNA clones have been described
previously (Hogan et al., 2009; Ober et al., 2004). The full-length dll4
cDNA was subcloned into the pCS2+ vector by first amplifying from a
full-length template cDNA clone (accession number BC117624; Open
Biosystems) using the PCR primers 5-GCGCGGATCCACCATG-
GCAGCTTGGCTCACCTTTC-3 and 5-GCGCTCTAGATTATACCT -
CAGTTGCTATGAC-3, followed by subcloning with BamHI and XbaI.
mRNA was transcribed from a KpnI-linearised template using SP6 RNA
polymerase and the mMessage mMachine Kit (Ambion) and injected at
200 pg/embryo. The full-length human wild-type FLT4 and I1034S mutant
constructs were cloned into the pCS2+ vector using primers 5-GCGCG-
GATCCACCATGCAGCGGGGCGCCGCGCT-3 and 5-GCGCTCTA-
GACTACCTGAAGCCGCTTTCTT-3 to amplify the cDNA from the
templates described above, with BamHI and XbaI digestion for cloning.
mRNA for the wild-type and mutant forms of human FLT4, sFLT4 and
zebrafish vegfc and vegfd was transcribed from NotI-digested template
using the SP6 RNA polymerase and the mMessage mMachine kit and
injected at the concentrations indicated.
Transgenesis
The stable, germline-transmitted TG(flt4:YFP)hu4881 transgenic line was
generated by recombining a citrine-neomycin cassette using Red/ET
Recombination Technology (Gene Bridges) into the BAC clone
DKEY-58G10 using the homology arm tagged PCR primers 5-
aacgcgcaggtttgctagaatatctaaaaccccggaggactggaaacctgACCATGGTGAGC -
AAGGGCGAGGAG-3 and 5-aagaagggaatcccaatccaaatc cgacag aaa -
aacgtaaaatctctcttTCAGAAGAACTCGTCAAGAAGGCG-3 (homology
arms are shown in lowercase). We found that BAC transgenesis produced
germline founders, but that embryos expressing YFP were highly
dismorphic and died at stages prior to 24 hpf (data not shown). Hence, 6.6
kb of the 5UTR of flt4 as well as the YFP coding sequence was PCR
amplified using Phusion high-fidelity PCR (Finnzymes) followed by cloning
into the miniTol2 transgenesis vector (Kawakami, 2005). Amplification
primers were 5-GCGCG AATTCTAAGCAAAGTCAGACCTTACT G -
TCC-3 and 5-CACGT ACGGTGTGGTAACG-3. One-cell stage embryos
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were co-injected with construct DNA (25 ng/l) and transposase mRNA (25
ng/l) and the progeny screened for germline transmission. Low-level-
expressing germline-stable lines were generated, but expression was found
to wane after 48 hpf, suggesting that the construct might not contain all the
necessary regulatory elements for late expression.
Imaging and expression analysis
In situ hybridisation was performed as previously described (Bussmann et
al., 2007). The tie2 (Lyons et al., 1998), flt4 (Thompson et al., 1998), vegfc
(Hogan et al., 2009), vegfd (Hogan et al., 2009), dll4 (Herpers et al., 2008)
and hey2 (Zhong et al., 2000) probes were prepared as previously described.
Embryos were mounted in 1% low melting point agarose in a culture dish
with a cover slip replacing the bottom. Imaging was performed with a Leica
SPE or SP5 confocal microscope (Leica Microsystems) using a 10 or 40
objective with digital zoom. Angiography was performed as previously
described (Kuchler et al., 2006).
RESULTS
expando is a flt4 signalling-deficient mutant
In a screen for developmental mutants that fail to form lymphatic
vessels, we identified the mutant expandohu4602 that lacked the
thoracic duct at 5 days post-fertilisation (dpf) while retaining blood
circulation (Fig. 1A-D). To determine the stage at which
lymphangiogenesis was first impaired in expando mutants, we
examined the phenotype in double-transgenic TG(fli1:GFP, kdr-
l:Cherry) embryos, in which trunk blood vessels express both GFP
and Cherry but lymphatic vessels express only GFP (Hogan et al.,
2009). We found that all trunk lymphatic vessels, including the
intersegmental lymphatic (islv) and dorsal longitudinal lymphatic
(dllv) vessels, were absent in expando mutants at 5 dpf and that
parachordal lymphangioblasts (PLs) had failed to bud from the PCV
and were absent at 54 hpf (Fig. 1E-H). We examined tie2 expression
at 48 hpf as a marker for venous-derived intersegmental vessels and
found that venous sprouts were absent in expando mutants (Fig.
1I,J), a phenotype identical to that of vegfc MO-injected embryos,
which lack all venous angiogenic sprouting (Hogan et al., 2009).
To identify the causative mutation for the expando phenotype, we
used a traditional positional cloning approach and found the
expando locus to be linked to a region of chromosome 14 containing
the flt4 gene (Fig. 2A). Sequencing of flt4 revealed a point mutation
predicted to change a conserved isoleucine residue into a serine at
position 1042 in the split kinase domain (Fig. 2B,C). To examine the
functional consequence of this mutation, we introduced the
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Fig. 1. Zebrafish expando mutants lack lymphatic vessels and
venous sprouting. (A,B)Lateral views of TG(fli1:GFP) expression in
wild-type (wt; A) and expando mutant (B) larvae at 5 dpf demonstrate
that overall vascular patterning is not perturbed in expando mutants.
(C,D)Overlay image of angiogram (red) and TG(fli1:GFP) (white)
indicating the presence of blood flow in wild-type (C) and mutant (D)
embryos. The thoracic duct (arrows) is present in the wild type, but
absent (asterisks) from mutant larvae. (E,F)Lateral views of wild type (E)
and expando mutant (F) in a double-transgenic TG(fli1:GFP),
TG(kdr-l:Cherry) background. All lymphatic vessels are absent in
mutants at 5 dpf. Arrows indicate the thoracic duct (td), intersegmental
lymphatic vessels (islv) and dorsal longitudinal lymphatic vessels (dllv) in
wild-type embryos. Asterisks indicate their absence in expando
mutants. (G,H)Parachordal lymphangioblasts (PLs) are absent from the
horizontal myoseptum in expando mutants (asterisk in H) as compared
with wild-type siblings (arrow in G indicates PL) in the double-
transgenic TG(fli1:GFP), TG(kdr-l:Cherry) background at 54 hpf. (I,J)tie2
expression in venous sprouts (arrows in I) is absent in expando mutants
(J). n6/29 embryos scored and confirmed by genotyping.
Fig. 2. A mutation in the flt4 kinase domain is responsible for the
expando phenotype. (A)Meiotic mapping links the expando locus to
a region of chromosome 14 containing flt4. Analysis of 131 zebrafish
embryos (262 meioses) identifies two recombination events at the
marker z43267 and three independent recombinants at the marker
z26376, thereby localising the mutation to a region containing flt4.
(B,C)Sequencing of the coding exons of flt4 reveals a T>G mutation
(see chromatogram in B) that changes a highly conserved isoleucine to
a serine at position 1042 of the predicted zebrafish Flt4 protein
sequence. Flt4 receptor structure is depicted, with Ig domain (I-VII),
transmembrane domain (TM) and split tyrosine kinase domain (TK1 and
TK2). Alignment of conserved sequences (C) demonstrates that I1042 is
a conserved residue, with grey shading indicating non-conserved
residues. (D)Tyrosine phosphorylation (pY; upper panel,
phosphotyrosine blot) was seen upon in vitro stimulation with VEGFC
of wild-type human FLT4, but not of I1034S mutant FLT4. Lower panel
(Flt4 protein blot) indicates the presence of FLT4 protein post-
transfection in the assayed samples. D
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equivalent mutation (I1034S) into human FLT4 and compared the
ability of VEGFC to stimulate kinase domain activity of the wild-
type and mutant forms of the receptor. We found that the I1034S
mutation led to a loss of kinase domain function in this in vitro assay
(Fig. 2D). Consistent with a flt4 mutation leading to the expando
phenotype, the injection of either a flt4-targeting morpholino
oligomer (MO) or an mRNA encoding the soluble Ig domain of
human FLT4 (sFLT4) that acts as a dominant inhibitor of Flt4
signalling in zebrafish (Ober et al., 2004), phenocopied the loss of
lymphatic vessels (Fig. 3G; data not shown) as previously described
(Kuchler et al., 2006; Yaniv et al., 2006). We hereafter refer to the
expando (Flt4 I1042S) mutant as flt4hu4602.
Angiogenesis defects of the primordial hindbrain
channel are observed in flt4 morphants, vegfc
morphants and sFLT4 mRNA-injected embryos, but
not in flt4hu4602 mutants
Previous studies have described angiogenesis defects after inhibition
of flt4 translation by MO injection (Covassin et al., 2006; Siekmann
and Lawson, 2007). We injected sFLT4 mRNA and also MOs
targeting the start codons of flt4 and vegfc. These injections
consistently induced angiogenesis defects during the formation of
the primordial hindbrain channel (PHBC) (Fig. 3C-E) in 20-40% of
injected embryos. When all injected embryos from the same clutch
were grown to 5 dpf, they completely lacked lymphatic vessels,
phenocopying the flt4hu4602 phenotype with 100% penetrance (Fig.
3F,G). The dependency of PHBC formation upon Vegfc and Flt4 in
zebrafish has been reported previously (Covassin et al., 2006).
Surprisingly, in contrast to the injected embryo phenotypes, detailed
examination of flt4hu4602 mutant embryos failed to reveal PHBC
defects (Fig. 3B).
Taken together, these observations suggest two distinct
possibilities: (1) that different thresholds of Flt4 signalling are
required for distinct angiogenesis events in the zebrafish embryo,
such that normal signalling is necessary for lymphangiogenesis and
venous angiogenesis, whereas very low-level, residual signalling in
the presence of the I1042S mutation is sufficient for PHBC
development; or (2) that a non-signalling function of Flt4 regulates
PHBC angiogenesis whereas signalling is indispensable for PCV
sprouting and lymphangiogenesis.
To evaluate the possibility of performing experiments to rescue
the morphant PHBC defect with mutant or truncated forms of Flt4,
we injected full-length mRNA encoding the human wild-type and
I1034S mutant forms of FLT4 (300 pg/embryo). Upon forced
expression, both of these mRNAs were capable of inhibiting
thoracic duct formation (wild-type FLT4 mRNA, 47% thoracic duct
deficient, n42; I1034S FLT4 mRNA, 26% thoracic duct deficient,
n31; data not shown), indicating that FLT4 has mild dominant-
negative activity upon overexpression by mRNA injection in
zebrafish, therefore precluding an attempt to rescue PHBC defects.
Excessive arterial angiogenesis caused by the
depletion of Dll4 is rescued in flt4hu4602 mutants
We next examined arterial development in flt4hu4602 mutants by
taking advantage of the TG(flt1:YFP)hu4624 transgenic line, in which
the arteries of the embryonic trunk are labelled by YFP (Hogan et
al., 2009). We examined the presence of the venous-derived ISV
components: these sprouts form during secondary sprouting from
the vein, connect to ISAs in order to establish intersegmental venous
vessels (Isogai et al., 2003) and are identifiable by the absence of flt1
expression in the ventral component of functional intersegmental
vessels at 3 dpf (Hogan et al., 2009). We found that like vegfc MO-
injected embryos (Hogan et al., 2009), flt4hu4602 mutants failed to
form intersegmental venous-derived vessels, and in the absence of
these venous sprouts an increased number of ISA connections to the
dorsal aorta were formed (Fig. 4A,B). Apart from the increased ISA
connections to the dorsal aorta, the ISAs appeared otherwise normal
in flt4hu4602 mutants.
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Fig. 3. Zebrafish flt4hu4602 mutants lack the PHBC defects observed upon flt4 MO, vegfc MO or sFLT4 mRNA injection. (A-E)Angiogenesis
of the primordial hindbrain channel (PHBC) fails to occur in flt4 MO-injected (5 ng/embryo) (C), sFLT4 mRNA-injected (200 pg/embryo) (D) and vegfc
MO-injected (E) embryos (yellow asterisk) as compared with wild-type controls (A), but is unaffected (yellow arrow) in individually genotyped
flt4hu4602 mutants (B) at 28 hpf. (F,G)Angiogenesis of the PHBC and lymphangiogenesis respond differently to injection of flt4 MO, vegfc MO and
sFLT4 mRNA. Injection of flt4 MO (5 ng/embryo) inhibits PHBC development in 29% of embryos at 28 hpf but inhibits lymphangiogenesis [thoracic
duct (TD) scored as readout] with 100% efficiency at 4 dpf in the same injection (n55 embryos scored). vegfc MO (5 ng/embryo) inhibits PHBC
development in 22% of embryos (n41) and TD development in 97% of embryos in the same injection (n37). sFLT4 mRNA (200 pg/embryo)
inhibits PHBC development in 42% of embryos and TD development in 100% of embryos in the same injection (n120). Uninjected control
embryos showed normal PHBC and TD development in 100% of cases (n20) at 28 hpf and 4 dpf (F,G). D
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Given the known relationship between Dll4 and Flt4 in
angiogenesis (Siekmann and Lawson, 2007; Tammela et al., 2008),
we injected a dll4 MO that recapitulated the previously described
dll4 loss-of-function arterial hyperbranching phenotype (Leslie et
al., 2007) into embryos derived from flt4hu4602 heterozygous crosses
(flt4hu4602+/–  flt4hu4602+/–). We found the hyperbranching
phenotype to be variable and sorted embryos displaying severe
arterial hyperbranching (e.g. Fig. 4C) from those not displaying
hyperbranching phenotypes (e.g. Fig. 4D) into separate groups for
genotyping. The mutant genotype was almost completely absent
from the severe phenotypic category (present in 1/29 genotyped
hyperbranching embryos) and was enriched in the non-
hyperbranching category (present in 21/55 genotyped embryos)
indicating a rescue of the arterial hyperbranching phenotype
associated with the mutant allele (Fig. 4E).
Excessive arterial angiogenesis caused by the
depletion of Dll4 is dependent on Vegfc
To test whether the flt4-dependent dll4 hyperbranching phenotype
is driven by Vegfc, we injected embryos with dll4 MO alone, dll4
MO with vegfc MO, or dll4 MO with sFLT4 mRNA. For all
treatments, the dll4 MO-induced arterial hyperbranching phenotype
was scored as either severe, mild or wild-type (no hyperbranching)
(for examples, see Fig. S1 in the supplementary material). The
injection of either vegfc MO or sFLT4 mRNA rescued the dll4
excessive angiogenesis phenotype at 72 hpf (Fig. 4F). We observed
no ISA defects upon injection of either vegfc MO or sFLT4 mRNA
at concentrations that completely inhibited lymphangiogenesis and
also rescued the dll4 phenotype.
flt4 and vegfc are expressed in arterial
endothelial cells during angiogenesis and their
expression is unaltered upon loss of dll4
To determine whether the phenotype could be explained by changes
in gene expression during arterial angiogenesis, we analysed the
expression of flt4, vegfc, vegfd (figf – Zebrafish Information
Network) and hey2 in dll4 morphants at 24 hpf. flt4 was expressed
in all ISAs and in the dorsal aorta at 24 hpf, but rapidly
downregulated thereafter, with expression vastly reduced in arteries
as compared with the PCV by 26 hpf (Fig. 5A,C). We carefully
staged dll4 MO-injected and uninjected control embryos at 24 hpf
(based on head angle and tail extension) and detected no appreciable
change in flt4 expression in the ISAs at 24 hpf (Fig. 5A,B) or later,
during downregulation of flt4 expression (25, 27, 29 and 31 hpf; see
Fig. S2 in the supplementary material), although we cannot exclude
the possibility of mild changes for which in situ hybridisation is
insufficiently sensitive to detect. Next, we generated a flt4 promoter-
driven transgenic line utilising a 6.6 kb fragment of the flt4 5UTR.
This promoter fragment drove expression of YFP in ISAs, the dorsal
aorta and the PCV in both wild-type and dll4 MO-injected embryos,
with no apparent change in expression levels in stage-matched
embryos (Fig. 5D,E). In dll4 morphants at 24 hpf, vegfc expression
in the dorsal aorta (Fig. 5F,G) and vegfd expression in the tailbud
(Fig. 5H,I) were unchanged. In addition, we observed no change in
the expression of hey2, indicating that developmental gene
expression programmes in arterial endothelial cells were largely
normal in dll4 MO-injected embryos (Fig. 5J,K).
dll4 morphant arteries are sensitised to increased
Vegfc during primary sprouting of intersegmental
arteries
The arterial phenotype induced by the loss of dll4 is not observed
before 28-32 hpf, after which time the ISAs progressively display
excessive angiogenesis and hyperbranching defects. Given that this
phenotype is dependent on Vegfc/Flt4 signalling, we hypothesised
that the introduction of excessive vegfc might increase the severity,
or alter the onset, of the phenotype. We introduced mRNA encoding
full-length zebrafish Vegfc into wild-type and dll4 MO-injected
embryos in the TG(flt1:YFP)hu4624 transgenic background and
examined the ISAs at 28 hpf, a time point preceding secondary
sprouting of vessels from the PCV and the arterial phenotype induced
by the knockdown of dll4. vegfc mRNA injection in combination
with dll4 MO synergistically induced aberrant sprouting of ISAs,
which turned bilaterally at approximately the level of the base of the
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Fig. 4. The dll4 morphant hyperbranching phenotype is rescued in flt4hu4602 mutants, vegfc morphants and sFLT4 mRNA-injected
embryos. (A-D)Lateral views of uninjected control (A) and flt4hu4602 mutant (B) as compared with wild-type (C) and flt4hu4602 mutant (D) zebrafish
embryos injected with dll4 MO. Images were taken in the TG(flt1:YFP)hu4624 background, labelling trunk arteries to reveal the failure to form
intersegmental venous sprouts in expando mutants (B, yellow arrows). The dll4 morphant arterial hyperbranching phenotype (C) is rescued in
flt4hu4602 mutants (D). Venous sprouts were identified by the absence of flt1:YFP expression in ISVs (brackets). Embryos at 72 hpf. (E)Arterial
hyperbranching phenotypes were scored post-injection of dll4 MO and subsequently genotyped. The mutant genotype was almost completely
absent from the severe category (e.g. C) (1/29 embryos, *P<0.01 by 2 test) and was enriched in the category not displaying hyperbranching (e.g.
D) (21/55 embryos, #P<0.01 by 2 test). (F)In transgenic TG(flt1:YFP)hu4624 embryos, co-injection with dll4 MO together with vegfc MO (green bars,
n57 embryos), or of dll4 MO together with sFLT4 mRNA (200 pg/embryo) (red bars, n67 embryos), led to rescue of the arterial hyperbranching
phenotype observed upon injection of dll4 MO alone (blue bars, n81 embryos). Arterial hyperbranching phenotypes were categorised as no
hyperbranching (none), mild or severe (see Fig. S1 in the supplementary material).
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neural tube in a distinctive manner (Fig. 5L-N,P). This phenotype
was robustly reproducible, was not present in embryos injected with
dll4 MO only, and occurred only rarely upon injection of vegfc
mRNA only (Fig. 5M,N,R). Interestingly, we also observed this
phenotype upon injection of full-length zebrafish vegfd mRNA, but
found no difference when vegfd mRNA was injected in combination
with dll4 MO (Fig. 5O,Q,R). Taken together, these data indicate that
in the absence of dll4, arterial cells are more responsive to
exogenously introduced vegfc at stages prior to venous sprouting,
confirming an early capability as well as an ongoing suppressive role
for dll4 during Vegfc/Flt4 signalling in arterial angiogenesis.
Overexpression of dll4 reduces sprouting from
venous endothelium
Taken together, the above data suggest that dll4, which is
restricted in expression to the early arteries in developing
embryos (Leslie et al., 2007; Siekmann and Lawson, 2007),
functions to suppress the response of arteries to Vegfc-mediated
Flt4 signalling. This would predict that ectopic dll4 in embryonic
veins might inhibit or reduce Vegfc/Flt4-driven venous sprouting.
To test whether this was the case, we injected mRNA encoding
full-length Dll4 into TG(flt1:YFP)hu4624 embryos and examined
the formation of venous sprouts at 52 hpf. We identified venous
sprouts by scoring the ventral segments of intersegmental vessels
that did not express TG(flt1:YFP)hu4624 at 52 hpf. dll4
overexpression led to cardiac defects and loss of circulation when
injected at high doses, but did not lead to the ectopic venous
expression of flt1 (data not shown). We selected embryos with
normal blood circulation and omitted embryos severely affected
by dll4 overexpression. When the number of venous sprouts
present across the first 12 intersegmental vessels anterior to the
cloaca was scored, there was a significant reduction in the number
of venous sprouts in injected embryos compared with uninjected
controls (Fig. 6).
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Fig. 5. Sprouting intersegmental arteries express flt4 and are sensitised to exogenously introduced Vegfc in the absence of dll4.
(A-E)At 24 hpf, the expression of flt4 is present in all arterial cells (A) and is unaltered upon loss of dll4 (B) (n40 uninjected control and n40 dll4
MO-injected embryos scored). By 26 hpf (C), flt4 is downregulated in the dorsal aorta (n20 embryos). Analysis of a flt4 promoter-driven transgenic
line identifies YFP expression in all arterial cells at 24 hpf (D). The expression of YFP is unaltered in dll4 MO-injected embryos (E). (F,G)At 24 hpf, the
expression of vegfc is present in the dorsal aorta (F) and is unaltered in dll4 MO-injected embryos (G) (n20 uninjected and n20 MO-injected
embryos). (H,I)The expression of vegfd in the tailbud is unaltered in dll4 MO-injected (I) as compared with uninjected control (H) embryos (n20
uninjected and n20 MO-injected embryos). (J,K)The expression of the arterial marker gene hey2 is unaltered in dll4 MO-injected (K) as compared
with uninjected control (J) embryos (n20 uninjected and n20 MO-injected embryos). (L-R)dll4 morphants are sensitised to exogenously
introduced vegfc mRNA during arterial angiogenesis. Forced expression by the injection of mRNA encoding full-length zebrafish Vegfc into dll4
MO-injected embryos (n133) (P) leads to aberrant ectopic bilateral turning of ISAs by 28 hpf (yellow arrows), which was never observed in wild-
type embryos (L) or in those injected with dll4 MO only (n90) (M). ISAs rarely turn bilaterally upon injection of vegfc mRNA only (n106) (N),
whereas injection of full-length vegfd mRNA robustly showed this phenotype without (n211) (O) or with (n227) (Q) dll4 MO. For each of the
conditions tested, the percentage of embryos showing wild-type, mild (aberrant ISAs spanning two somites) or severe (aberrant ISAs spanning more
than two somites) ISA phenotypes is shown in R.
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Flt4 signalling is required for zebrafish
lymphangiogenesis and venous sprouting
Here we describe a new zebrafish flt4 mutant phenotype that is
caused by an amino acid substitution in the conserved split kinase
domain of Flt4 (I1042S). Using this in vivo model, we have shown
a strict requirement for normal Flt4 signalling for venous
angiogenesis. We find that primary angiogenesis of ISAs can occur
independently of normal Flt4 signalling in zebrafish. This finding is
consistent with previous studies suggesting that ISA sprouting is
chiefly regulated by Vegfa, Kdr and Kdr-l (Bahary et al., 2007;
Covassin et al., 2006; Habeck et al., 2002; Lawson et al., 2003), but
suggests that previously described ISA morphant phenotypes for
Vegfc and Flt4 do not reflect a requirement for wild-type kinase
domain activity of the Flt4 receptor (Covassin et al., 2006). The
defects in secondary sprouting from the veins observed in flt4hu4602
mutants are apparently identical to the previously described
phenotypes of full of fluid (ccbe1) mutants and vegfc morphants
(Hogan et al., 2009).
flt4 MO, vegfc MO or sFLT4 mRNA injections led to the failure
of PHBC development, but the defects were far less penetrant than
the lymphangiogenesis failure seen within the same injection
experiments and were not observed in flt4hu4602 mutants. These data
suggest (1) that there is a differential dosage sensitivity for Flt4
signalling during different angiogenesis events and/or (2) that some
degree of flt4-regulated angiogenesis might occur independently of
kinase domain function. The scenario described here closely
resembles that observed in the mouse, in which mutants for Vegfc,
double mutants for Vegfd and Vegfc, or a hypomorphic Flt4 allele,
all produce lymphatic vascular-specific defects, whereas the
complete loss of Flt4 leads to defects in haemangiogenesis and early
lethality (Dumont et al., 1998; Haiko et al., 2008).
Dll4 function provides a mechanism by which
arteries, but not veins, suppress the response to
Vegfc-driven Flt4 signalling during development
Despite the lack of a marked arterial phenotype in flt4hu4602 mutants,
we find that flt4 is actively transcribed in the ISAs and the dorsal
aorta, concurrent with sprouting arterial angiogenesis at 24 hpf.
Furthermore, a source of Vegfc is present in the trunk derived from
the dorsal aorta during this period. The severe hyperbranching
phenotypes observed in the absence of dll4 are dependent on Vegfc
and on Flt4 kinase domain activity, indicating that one function of
dll4 is to suppress the arterial response to Vegfc/Flt4 signalling in
developing arteries of the trunk. Consistent with this, Dll4-depleted
arteries are sensitised to increased Vegfc levels supplied
exogenously by mRNA injection, and the overexpression of dll4
reduces venous sprouting, which is dependent on Vegfc/Flt4
signalling. Hence, the severe, progressive arterial hyperbranching
phenotype that has been described previously upon loss of dll4 in
zebrafish is predominantly a consequence of failing to suppress the
ability of developing arteries to respond to endogenous Vegfc/Flt4
signalling. A working model summarising the contribution of Dll4
in the context of arterial and venous angiogenesis and Vegfc/Flt4
signalling is outlined in Fig. 7.
Changes in vegfc or flt4 expression do not explain
the suppression of the arterial response to
Vegfc/Flt4 signalling
We find that flt4 transcript levels are progressively downregulated
in developing arteries after 24 hpf, an event that is likely to
contribute to lowering the responsiveness of arteries to endogenous
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Fig. 6. Overexpression of dll4 reduces sprouting from the PCV.
(A,B)Injection of mRNA encoding full-length Dll4 into TG(flt1:YFP)hu4624
zebrafish embryos leads to a reduction in the number of venous sprouts
in injected (B) as compared with uninjected control (A) embryos at 52
hpf. ISAs that connect directly to the dorsal aorta (red bar) are indicated
by yellow arrows. Venous spouts (yellow brackets) can be readily
identified by the absence of TG(flt1:YFP)hu4624 expression in the ventral
component of an intersegmental vessel. Venous sprouts connect
directly to the posterior cardinal vein (blue bar) from which they derive
during secondary sprouting. (C)Quantification of the number of venous
sprouts (y-axis) on one side of the embryo across 12 segments anterior
to the cloaca (n23 embryos scored for both dll4 MO-injected and
uninjected controls). dll4 MO-injected embryos show a significant
decrease in the number of intersegmental venous sprouts (P<0.001,
Mann-Whitney rank sum test).
Fig. 7. Dll4 inhibits arterial Vegfc/Flt4 signalling in the
developing zebrafish trunk. (A-C)Expression analysis at 24 hpf for
dll4 (A), flt4 (B) and vegfc (C) indicates the arterial restricted expression
of dll4, expression of flt4 in all venous and arterial cells, and expression
of vegfc restricted to the dorsal aorta. (D)Schematic overview of the
developing vasculature in the zebrafish trunk. DA, dorsal aorta; PCV,
posterior cardinal vein; ISA, intersegmental artery; ISV, intersegmental
vein; PL, parachordal lymphangioblast. (E)Working model of the
interplay between Dll4 and Vegfc/Flt4 signalling. Previous studies have
shown that vegfa (vegfaa and vegfab duplicates in zebrafish) is
necessary for ISA development [a (Bahary et al., 2007; Nasevicius et al.,
2000)], that vegfc influences (dashed line) ISA development
[b (Covassin et al., 2006)] and that the receptors kdr and kdr-l mediate
intracellular signalling to control ISA development [c (Bahary et al.,
2007; Covassin et al., 2009; Covassin et al., 2006; Habeck et al., 2002;
Lawson et al., 2003; Meng et al., 2008)]. We have previously shown
that vegfd is unlikely to play a role in ISA development owing to its
restricted expression [d (Hogan et al., 2009)]. Here we demonstrate that
signalling through the Flt4 kinase domain (KD) does not contribute to
ISA development as it is suppressed by Dll4 (dotted lines indicate that
the mechanism of suppression is unknown). In the absence of Dll4,
endogenous Vegfc drives a Flt4 (KD)-dependent ISA hyperbranching
phenotype. In the vein (which does not express dll4), Vegfc/Flt4
signalling is indispensable for normal venous angiogenesis and
lymphangiogenesis. D
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Vegfc. However, the increased responsiveness of dll4 morphants to
Vegfc/Flt4 signalling does not coincide with changes in vegfc or flt4
transcription. In particular, there is no change in vegfc or flt4
expression in dll4 morphants during the formation of primary
arterial sprouts (24-31 hpf), despite the fact that these sprouts are
sensitised to increased levels of vegfc at early stages, prior to 28 hpf
(Fig. 5). This indicates that dll4 can regulate Vegfc/Flt4 signalling
at a level independent of vegfc or flt4 transcription. In zebrafish, it
has been demonstrated previously that notch1b knockdown, or
chemical treatment with a -secretase inhibitor (DAPT) that blocks
the cleavage of the Notch intracellular domain (Geling et al., 2002),
leads to the same increased exploratory behaviour of arterial
endothelial cells that is observed upon dll4 loss-of-function (Leslie
et al., 2007). This correlation is suggestive of dll4 acting through
intracellular Notch signalling and would indicate that altered
transcription should precede an altered response to VegfC/Flt4
signalling. In this context, the unchanged expression of the key
molecular players (flt4, vegfc, vegfd) in dll4 morphants implies that
other, as yet unidentified, molecular regulators are involved.
Interestingly, we find that vegfd mRNA injection alone can lead
to the early ectopic turning of developing ISAs, but these defects
were not enhanced upon knockdown of dll4. Vegfd has varying
capabilities in mammals: for example, it is a Flt4-specific ligand in
mouse but, like VEGFC, can bind to both VEGFR2 (KDR) and
FLT4 in humans (Baldwin et al., 2001). The capability of Vegfd to
stimulate aberrant angiogenesis of ISAs is likely to explain why the
embryonic expression of vegfd is highly restricted to the tailbud
during zebrafish development (Fig. 5) (Hogan et al., 2009). This
restriction of vegfd expression would be required for normal arterial
angiogenesis to occur in the absence of Flt4 activation.
Comparison of expression patterns and
phenotypes for different Notch signalling
components suggests combinatorial and context-
dependent roles during angiogenesis
In the developing mammalian retina, both dll4 and flt4 display
restricted expression in tip cells during angiogenesis (Hellstrom et
al., 2007; Tammela et al., 2008). In zebrafish, we did not see any
restricted expression of flt4 in tip cells at 24 hpf during ISA
angiogenesis, and dll4 expression is found in all arterial cells at this
stage [as discussed by Leslie et al. (Leslie et al., 2007)]. In the
developing mouse trunk, Flt4 expression is also seen in all arterial
cells of the intersegmental vasculature, although it is enriched in tip
cells when assayed by immunohistochemistry (Tammela et al.,
2008). These data suggest context-dependent differences in the
expression patterns of Flt4 and Dll4.
Previous studies in zebrafish have shown that mind bomb mutants
(which cause a block in intracellular Notch signalling) have
upregulated flt4 expression throughout the developing arterial
system (Lawson et al., 2001), and rbpsuh morphants have
upregulated expression specifically in the tip cells of arterial sprouts
(Siekmann and Lawson, 2007). However, we found no marked
increase in flt4 expression in dll4 morphants by in situ hybridisation,
suggesting significant differences between loss-of-function
phenotypes for different Notch pathway components during
angiogenesis. Furthermore, the phenotype seen upon MO
knockdown of Rbpsuh is observed earlier than that of dll4
morphants or mutants. Dramatically increased arterial angiogenesis
is seen in rbpsuh morphants during the initial stages of primary
sprouting (Siekmann and Lawson, 2007), whereas dll4 morphants
or mutants (Leslie et al., 2007) do not display defects until hours
later. Given that multiple Notch ligands are expressed and capable
of acting during angiogenesis in vertebrates (Benedito et al., 2009;
Lawson et al., 2001; Smithers et al., 2000), it is likely that the
combinatorial use of ligands contributes to these differences in the
loss-of-function phenotypes. It seems plausible that differences in
Notch ligand or receptor gene expression patterns and activities
could be very widely utilised to allow for unique, context-dependent
and restricted Vegf signalling outputs in order to generate diverse
spatial and temporal responses during angiogenesis in the embryo
or adult.
Taken together, the above findings indicate that one function of
arterial Dll4 is to inhibit the responsiveness of arteries to Vegfc,
whereas the development of the venous and lymphatic lineages
(which do not express dll4) are completely dependent on Vegfc/Flt4
signalling in the developing zebrafish trunk. This mechanism
contributes to the differential response of arteries and veins to a
constant source of Vegfc in the embryonic trunk and further
characterises a specific role of the Notch ligand Dll4 in regulating
the Vegfc/Flt4 signalling axis.
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